Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
Recruiting
Phase 4
Interventional Study
Dry Eye
Meibomian Gland Dysfunction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 65 (estimated)
- Sponsor
- University of California, Berkeley · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Is 18 years of age and has full legal capacity to volunteer (no max age requirement)
* Baseline Ocular Surface Disease Index (OSDI) \>13
* Has mild to moderate MGD
* Has best corrected visual acuity of 20/40 or better
* Has had an oculo-visual examination in the last two years…
Contacts